The introduction of biologics since 2000 has improved quality of life of patients and has led to a steady decrease in hospitalization and surgery for IBD.[7–9] A meta-analysis reported that anti-TNF biologics reduced the odds of hospitalization for CD and UC by more than half and surgery by 33% to 77%.[10] However, studies on whether the proportion of ED visits by IBD patients has decreased are scarce. The gene discussed is TNF; the disease is inflammatory bowel disease.